Journal
BONE
Volume 96, Issue -, Pages 45-50Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2016.11.024
Keywords
Sclerostin; Wnt; Osteoarthritis; Ankylosing spondylitis; Rheumatoid arthritis
Categories
Funding
- National Institutes of Health [R01 AR067129, R01 AR65402, K01 AR070281]
- Robert and Arlene Kogod Center on Aging Career Development Award
Ask authors/readers for more resources
Sclerostin, the product of the SOSTgene, is a secreted inhibitor of Wnt signaling that is produced by osteocytes to regulate bone formation. While it is often considered an osteocyte-specific protein, SOST expression has been reported in numerous other cell types, including hypertrophic chondrocytes and cementocytes. Of interest, SOST/sclerostin expression is altered in certain pathogenic conditions, including osteoarthritis and rheumatic joint disease, and it is unclear whether sclerostin plays a protective role or whether sclerostin may mediate disease pathogenesis. Therefore, as anti-sclerostin antibodies are being developed for the treatment of osteoporosis, it is important to understand the functions of sclerostin beyond the regulation of bone formation. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available